Financials

News Discussions Technicals Seasonals

SENZA fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

SenzaGen AB engages in the development of in vitro test methods for prediction of chemical and protein sensitizers. It offers services for assessment of sensitizers for industry and regulatory purposes, using its proprietary technology called GARD (Genomic Allergen Rapid Detection). It serves clients in cosmetic, chemical, pharmaceutical, and food industries. The company was founded by Malin Marie Lindstedt and Carl Arne Krister Borrebaeck on August 18, 2010 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

SENZA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company